Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: Long-term follow-up results

Journal of Clinical Oncology

Volumn 21, Issue 6, 2003, Pages 1057-1065

  Vuylsteke, R J C L M ^a   Van Leeuwen, P A M ^a   Muller, M G Statius ^a   Gietema, H A ^a   Kragt, D R ^a   Meijer, S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; HUMAN; LONG TERM CARE; LYMPH NODE DISSECTION; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; FEMALE; FOLLOW UP; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME;

FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037445262     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.170     Document Type: Article

References (35)

1. Balch CM, Soong SJ, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255-263, 1996
2. Cascinelli N, Morabito A, Santinami M, et al: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial - WHO Melanoma Programme. Lancet 351:793-796, 1998
3. Drepper H, Kohler CO, Bastian B, et al: Benefit of elective lymph node dissection in subgroups of melanoma patients: Results of a multicenter study of 3616 patients. Cancer 72:741-749, 1993
4. Sim FH, Nelson TE, Pritchard DJ: Malignant melanoma: Mayo Clinic experience. Mayo Clin Proc 72:565-569, 1997
5. Veronesi U, Adamus J, Bandiera DC, et al: Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49:2420-2430, 1982
6. Sim FH, Taylor WF, Ivins JC, et al: A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: Preliminary results. Cancer 41:948-956, 1978
7. Balch CM, Soong S, Ross MI, et al: Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7:87-97, 2000
8. Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399, 1992
9. Reintgen D, Cruse CW, Wells K, et al: The orderly progression of melanoma nodal metastases. Ann Surg 220:759-767, 1994
10. Thompson JF, McCarthy WH, Bosch CM, et al: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5:255-260, 1995
11. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
12. Statius Muller MG, Borgstein PJ, Pijpers R, et al: Reliability of the sentinel node procedure in melanoma patients: Analysis of failures after long-term follow-up. Ann Surg Oncol 7:461-468, 2000
13. Veen Hvd, Hoekstra OS, Paul MA, et al: Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 81:1769-1770, 1994
14. Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al: The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 91:2401-2408, 2001
15. Albertini JJ, Cruse CW, Rapaport D, et al: Intraoperative radiolympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 223:217-224, 1996
16. Alex JC, Weaver DL, Fairbank JT, et al: Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 2:303-308, 1993
17. McMasters KM, Reintgen DS, Ross MI, et al: Sentinel lymph node biopsy for melanoma: How many radioactive nodes should be removed? Ann Surg Oncol 8:192-197, 2001
18. Diest PJv, Peterse HL, Borgstein PJ, et al: Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 26:S43-S49, 1999 (suppl)
19. Gershenwald JE, Thompson W, Mansfield PF, et al: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983, 1999
20. Morton DL, Thompson JF, Essner R, et al: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial -Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230:453-463, 1999
21. Gershenwald JE, Colome MI, Lee JE, et al: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16:2253-2260, 1998
22. Wagner JD, Corbett L, Park HM, et al: Sentinel lymph node biopsy for melanoma: Experience with 234 consecutive procedures. Plast Reconstr Surg 105:1956-1966, 2000
23. Jansen L, Nieweg OE, Peterse JL, et al: Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 87:484-489, 2000
24. Nguyen CL, McClay EF, Cole DJ, et al: Melanoma thickness and histology predict sentinel lymph node status. Am J Surg 181:8-11, 2001
25. Thompson JF: The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Ann Surg Oncol 8:44S-47S, 2001 (suppl)
26. Statius Muller MG, van Leeuwen PAM, van Diest PJ, et al: Pattern and incidence of first site recurrences following sentinel node procedure in ; melanoma patients. World J Surg 26:1405-1411, 2002
27. Essner R, Rose M, Kojima M, et al: Predicting the natural history of melanoma after tumor-negative sentinel lymph node dissection. Proc Am Soc Clin Oncol 20:xxx, 2001 (abstr 1397)
28. Cascinelli N, Belli F, Santinami M, et al: Sentinel lymph node biopsy in cutaneous melanoma: The WHO Melanoma Program experience. Ann Surg Oncol 7:469-474, 2000
29. Essner R, Conforti A, Kelley MC, et al: Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early- stage melanoma. Ann Surg Oncol 6:442-449, 1999
30. Dessureault S, Soong SJ, Ross MI, et al: Improved staging of node-negative patients with intermediate to thick melanomas (> 1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8:766-770, 2001
31. Marghoob AA, Koenig K, Bittencourt FV, et al: Breslow thickness and Clark level in melanoma: Support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer 88:589-595, 2000
32. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
33. Cascinelli N, Clemente C, Bifulco C, et al: Do patients with tumor-positive sentinel nodes constitute a homogeneous group? Ann Surg Oncol 8:35S-37S, 2001 (suppl)
34. Borgstein PJ, Meijer S, van Diest PJ: Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 6:315-321, 1999
35. McMasters KM, Reintgen DS, Ross MI, et al: Sentinel lymph node biopsy for melanoma: Controversy despite widespread agreement. J Clin Oncol 19:2851-2855, 2001